The cell-surface glycoprotein CD56 has three major isoforms that play important roles in cell adhesion and signalling, which may promote cell proliferation, differentiation, survival, or migration. It is an important molecule in normal kidney development and acts as a key marker in Wilms' tumour stem and progenitor cells. Here, we characterise the structural and genetic features of the CD56 glycoprotein, and examine its the roles in the normal versus diseased metanephric blastema. We reveal areas of CD56-related research that may complement or improve existing Wilms' tumour treatment strategies. A current investigated targeted Wilms' tumour treatment involves the antibody-drug conjugate lorvotuzumab mertansine that binds to CD56, for which a phase II trials was recently initiated.
Introduction
CD56, or Neural Cell Adhesion Molecule-1 (NCAM-1), is a cell-surface glycoprotein expressed early in development by various cell types [1,2]. CD56 molecules on adjacent cells adhere mainly to one another, but can be activated by other signaling molecules (e.g. ECM components, and cellsurface receptors) [2-4]. CD56 influences cell migration, proliferation, differentiation, apoptosis, and more specifically kidney organogenesis [2,5,6]. Unfortunately, CD56 might also be essential for Wilms' tumor (WT), as WT originates from the abnormal development of the metanephric blastema, and studies ranging from Fluorescence Assisted Cell Sorting (FACS) immuno-sorting to clonogenicity assays demonstrate the blastemal localization of CD56 [7, 8] .
Here, we review the structural and genetic features of CD56, its functions in normal kidney development and possible roles in WT, as well as novel treatment strategies targeting CD56. Although overall WT survival rates have risen to 90% over the last four decades, the mortality rate is near 50% for patients who relapse. If effective, CD56-specific treatments could in theory improve survival rates and reduce complementary treatment burden (chemotherapy and radiotherapy) and the adjacent risk of significant side effects [9] .
Methods
We searched (Sept. 2015) the NCBI database PubMed for recent research articles, using key words like 'CD56', 'Wilms' tumor' or 'nephroblastoma', 'oncogenesis', and 'kidney development'. To get a more comprehensive review, we also screened for additional relevant references in the identified publications. This meant researching the older citations relevant to CD56 in the newer publications. In total, 96 relevant publications were identified, of which 63 were included in this review.
The Three Major CD56 Isoforms
CD56 has at least 24 isoforms generated by alternative splicing, three of which are considered major: CD56-120kDa, CD56-140kDa and CD56-180kDa [2,10] (Fig. 1) . Here, the molecular weight refers to their non-glycosylated and non-sialylated forms [11] . It is unknown if alternative splicing is triggered by differential selection of splice or polyadenylation sites [12] , or exactly which biochemical factors regulate it. CD56-120kDa is the most common isoform in normal adult kidney tissue, whereas CD56-140kDa is the salient isoform in embryonic development, CD56 + malignancies, and tumor cell lines [2,13] (Table 1) . In other words, CD56-140kDa and CD56-180kDa are expressed during kidney organogenesis, before expression switches to CD56-120kDa in the later stages of Mesenchymal-to-Epithelial Transition (MET) as the kidney becomes developed [14] .
The major isoforms share a constant N-terminal ectodomain, comprising five contiguous C2-type immunoglobulin (Ig)-like domains, and two fibronectin type III-like (F3) domains [15-17] (Fig. 2  and 3 ). However, they interact differently with the cell surface. Whilst CD56-120kDa is linked to the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor and lacks a cytoplasmic domain, the other two major isoforms have a single transmembrane domain with cytoplasmic tails of different lengths 
Cell-Cell and Cell-Matrix Adhesive Properties Of CD56
CD56 mediates cell-cell adhesion via homophilic interactions (Fig. 4) 
CD56 Signalling Pathways
CD56 activation leads to the assembly of a signaling complex for several pathways (Fig. 5) . Since CD56-120kDa lacks a cytosolic domain, it is mainly involved in cell adhesion, as it cannot bind to intracellular signaling proteins and transduce signals on its own. However, if CD56-120kDa forms part of a complex, it may still participate in signal transduction. CD56 also initiates different signaling pathways, depending on whether it is localized in lipid rafts. For instance, CD56-140kDa outside lipid rafts activates FGFR-1 [4], whereas CD56-140kDa in lipid rafts activates p59
Fyn ; mutation of palmitoylation sites on CD56 or lipid raft destruction prevents p59
Fyn activation [32,33]. Here, we summarize a few important signaling pathways mediated by CD56. Meanwhile, FRS-2α is constitutively bound to the intracellular juxtamembrane domain of FGFR-1. It activates the MAPK ERK1/2 signaling pathway by recruiting GRB2 and SOS [37], further driving cell proliferation or differentiation. FRS-2α also activates Phosphoinositol 3-Kinase (PI3K), which promotes Akt-mediated cell survival [35] . The involvement of these proteins was proven by CD56 inducing sustained phosphorylation of FRS-2α, Akt and Src, as well as temporary phosphorylation of ERK1/2 [37] . In addition, the MAPK ERK1/2 signaling pathway leads to the inside-out activation of β1-integrin, thus influencing cell-matrix adhesion [4].
CD56-FGFR-1 Signalling Pathways

CD56-p59 Fyn Signaling Pathways
The cytosolic tail of CD56-140kDa and CD56-180kDa binds directly to both regulatory and nonreceptor Tyr-kinases. These include the cytosolic Src-family Tyr-kinase p59 Fyn . This further suggests that CD56 might play significant roles in WT onset. However, an immuno-staining experiment conducted in 2014 showed that CD56 is not solely a WT blastemal marker. In an immuno-staining experiment conducted last year, CD56 stained the epithelial and stromal components of WT more frequently than two other putative markers (CITED1 and SIX1), and the blastemal components less frequently [53] .
CD56 might play a significant role in WT diagnosis, given that it is also a marker in other forms of cancers in the nervous, immune, and neuroendocrine systems. In fact, CD56 over-expression correlates with tumor aggression and higher mortality rates in some cancer types 
Roles of CD56 in Normal Kidney Development and Wilms' Tumor
During early normal kidney development and MET, the high CD56 expression, coupled with the large initial presence of its embryonic isoforms, ensures significant activation of p59 Fyn and FAKs. This not only mediates integrin-binding but also activates the MAPK ERK1/2 and PI3K/Akt signaling pathways, thus promoting cell proliferation and survival respectively [9,50]. Therefore, the metanephric blastema expands and differentiates into epithelia. The binding of FAKs to integrin may also facilitate migration of the epithelial cells for recruitment into the epithelium by the ureteric bud.
As the kidney becomes gradually developed, CD56 expression switches to the 120-kDa isoform [14] , which lacks a cytosolic domain to activate p59 Fyn or FAKs. Perhaps then the ability of CD56-120kDa to form stronger cell-cell interactions in the epithelium, due to their shorter poly(sialic acid) chains, takes precedence, permitting maintenance of epithelial integrity. However, in WT, CD56 expression switches back to the 140-kDa isoform [14] , and CD56 down-regulation is reversed [57] .
As p59
Fyn and FAKs are re-activated, the MAPK ERK1/2 and PI3K/Akt signaling pathways that promote cell proliferation and survival are triggered, reversing or blocking MET and causing tumorigenesis. In addition, the longer poly(sialic acid) chains on CD56-140kDa weaken cell-cell adhesion due to increased electrostatic repulsion, increasing the likelihood of EMT and metastasis of cells from the tumor [17, 26] .
Although FGFR-1 has been implicated in normal kidney development, it is unknown whether it could be activated by CD56 to promote WT. FGFR-1 is expressed mainly in metanephric blastemal cell lineages [35] , increasing its likelihood of co-localization with CD56. If CD56-FGFR-1 signaling pathways exist in WT blastemal cells, they could enhance the enlargement of the WT blastema and promote the dedifferentiation of more committed WT progenitor cells into WT stem cells via EMT.
Finally, although CD56 mediates cell-matrix adhesion, WT blastema shows an almost complete lack of ECM proteins. This is consistent with the production of an incomplete ECM when normal tissue becomes cancerous, which allows more space in the kidney tissue for WT blastemal cells to invade [58] . Around the very early stages of MET (before the differentiation of the WT blastemal cells is arrested), the metanephric mesenchyme slowly loses its original ECM containing fibronectin and collagens I and III due to cap condensation, allowing a new basement membrane to be synthesized in place [59] . Fibronectin loss is in fact synchronized with the initial CD56 upregulation to ensure stronger cell-cell adhesion during MET [44] .
Nevertheless, cancer cells that undergo metastasis and migrate still have to pass through the normal matrix secreted by adjacent non-cancerous cells. To facilitate this passage, the α3 and α6 integrin subunits, which are indirectly activated by CD56, bind to fibronectin and laminin in the interstitial and basal membranes [58] . Thereafter, since metastasis is not driven by CD56-mediated inside-out signaling [4], perhaps it is promoted by the reduced affinity of CD56 homophilic binding and in turn cell-cell adhesion as a result of longer poly(sialic acid) chains on CD56-140kDa.
Upon binding to HSPGs, CD56 undergoes a conformational change for stronger cis-homophilic interactions and in turn cell-cell adhesion. Hence, the absence of HSPGs in the extracellular milieu of the WT blastema results in weaker cell-cell adhesion, further blocking MET and promoting EMT. Then, in the later stages of WT, when the cancer cells have migrated from the WT blastema to the basement membrane of the kidney and angiogenesis has occurred, the interaction between CD56 and HSPGs might promote metastasis by allowing cancer cells to bind to the vascular endothelium and undergo extravasation. Moreover, HSPGs in the basement membrane may concentrate growth factors like EGF and FGF, which might be necessary for the proliferation and migration of cancer cells [28] .
Clinical Applications
Despite the excellent overall survival (approx. 90%) for WT, almost 15% of patients relapse, usually within two years of diagnosis. WT subgroups with high-risk tumor histopathology (blastemal or diffuse anaplasia) and metastatic disease are of the highest risk. Even with optimized treatment of surgery, radiotherapy, and chemotherapy, sometimes including high-dose chemotherapy with stem-cell rescue therapy, more than one third of all relapsed patients do not survive [60] . Hence, with our increased understanding of the pathways and driver mutations involved in WT tumorigenesis comes the push to identify and add targeted therapy.
In the modern clinical setting, WT patients with a second relapse or refractory disease may be enrolled in early phase trials. However, the promising results seen in the laboratory of targeted therapy have not yet translated into a clinical difference. Challenges in testing targeted therapy include the scarcity of patients with refractory or relapsed disease, the rapid progression of relapse, and the genetic heterogeneity of WT.
Currently, studies recruiting children with pediatric solid tumors and WT are mushrooming. Ongoing early phase trials assessing targeted therapies include the EGFR inhibitor erlotinib, the VEGFR inhibitor ramucirumab, the PARP inhibitor talazoparib, and the exportin inhibitor selinexor. One interesting class of immuno-targeted therapy comprises antibody-drug conjugates targeting CD56 expressed on WT metanephric blastema [51] . These include IMGN901 (lovotuzumab), which is a conjugate between a humanized monoclonal antibody (huN901) that binds to CD56, and a maytansinoid (DM1) that inhibits the cell division cycle of excessively promoting tumor cells 
Conclusion
CD56 is a glycoprotein involved in normal kidney development and a marker in WT. Further research is needed to fully understand its genetic features and its function in normal versus diseased blastemal development. CD56 targeted therapy is currently undergoing early phase testing for WT and other childhood cancers.
Conflict of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article. 
